LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 397

Search options

  1. Article ; Online: Perspectives on COVID-19 and cancer immunotherapy: a review series.

    Goldman, Jason D / Ascierto, Paolo Antonio

    Journal for immunotherapy of cancer

    2021  Volume 9, Issue 3

    MeSH term(s) Humans ; COVID-19/complications ; COVID-19/immunology ; COVID-19/virology ; Disease Management ; Immunotherapy/adverse effects ; Immunotherapy/methods ; Neoplasms/complications ; Neoplasms/immunology ; Neoplasms/therapy ; Review Literature as Topic ; SARS-CoV-2
    Language English
    Publishing date 2021-03-11
    Publishing country England
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2021-002489
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Editorial: Combination Strategies in the Treatment of Melanoma.

    Ascierto, Paolo Antonio

    Frontiers in oncology

    2016  Volume 6, Page(s) 67

    Language English
    Publishing date 2016-03-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2016.00067
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.

    Trojaniello, Claudia / Sparano, Francesca / Cioli, Eleonora / Ascierto, Paolo Antonio

    Current oncology reports

    2023  Volume 25, Issue 6, Page(s) 623–634

    Abstract: Purpose of review: The treatment strategy for BRAF-mutated melanoma remains unsatisfactory, although the advent of immune checkpoint inhibition has improved the prognosis of advanced melanoma. This article reports current evidence on the efficacy and ... ...

    Abstract Purpose of review: The treatment strategy for BRAF-mutated melanoma remains unsatisfactory, although the advent of immune checkpoint inhibition has improved the prognosis of advanced melanoma. This article reports current evidence on the efficacy and safety of sequential immunotherapy with targeted therapy in patients with BRAF-mutated melanoma. It discusses criteria for the use of available options in clinical practice.
    Recent findings: Targeted therapy provides rapid disease control in a relatively high proportion of patients, although the development of secondary resistance limits the duration of responses; in contrast, immunotherapy may induce slow but more durable responses in a subset of patients. Therefore, the identification of a combination strategy for the use of these therapies seems a promising perspective. Currently, inconsistent data have been obtained, but most studies indicate that the administration of BRAFi/MEKi prior to immune checkpoint inhibitors appears to reduce the efficacy of immunotherapy. On the contrary, several clinical and real-life studies suggest that frontline immunotherapy with subsequent targeted therapy may be associated with better tumor control than immunotherapy alone. Larger clinical studies are ongoing to confirm the efficacy and safety of this sequencing strategy for treating BRAF-mutated melanoma with immunotherapy followed by targeted therapy.
    MeSH term(s) Humans ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins B-raf/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Mutation ; Melanoma/drug therapy ; Melanoma/genetics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Immunotherapy
    Chemical Substances Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Protein Kinase Inhibitors ; BRAF protein, human (EC 2.7.11.1)
    Language English
    Publishing date 2023-03-30
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057359-5
    ISSN 1534-6269 ; 1523-3790
    ISSN (online) 1534-6269
    ISSN 1523-3790
    DOI 10.1007/s11912-023-01402-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5521: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont

    Weber, Jeffrey / Mandala, Mario / Ascierto, Paolo Antonio / Larkin, James

    Journal for immunotherapy of cancer

    2022  Volume 10, Issue 1

    MeSH term(s) Humans ; Melanoma ; Skin Neoplasms
    Language English
    Publishing date 2022-01-18
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2021-004347
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Immunotherapy in non-melanoma skin cancer: updates and new perspectives.

    Ascierto, Paolo Antonio / Schadendorf, Dirk

    Drugs in context

    2019  Volume 8, Page(s) 212583

    Language English
    Publishing date 2019-03-25
    Publishing country England
    Document type Journal Article
    ZDB-ID 2719560-0
    ISSN 1740-4398 ; 1745-1981
    ISSN (online) 1740-4398
    ISSN 1745-1981
    DOI 10.7573/dic.212583
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Updates and new perspectives in nonmelanoma skin cancer therapy: highlights from 'Immunotherapy Bridge'.

    Ascierto, Paolo Antonio / Garbe, Claus

    Immunotherapy

    2020  Volume 12, Issue 3, Page(s) 167–174

    Abstract: Over the last few years, extensive research has improved our understanding of tumor immunology and has enabled the development of novel treatments. The state of the art of immunotherapy in various types of malignancies was exhaustively discussed in the ' ... ...

    Abstract Over the last few years, extensive research has improved our understanding of tumor immunology and has enabled the development of novel treatments. The state of the art of immunotherapy in various types of malignancies was exhaustively discussed in the 'Immunotherapy Bridge' meeting, which was held in Naples on 4-5 December 2019. Highlights related to the immunological treatment of nonmelanoma skin cancer are the content of this article.
    MeSH term(s) Antineoplastic Agents, Immunological/therapeutic use ; Carcinoma/immunology ; Carcinoma/pathology ; Carcinoma/therapy ; Clinical Trials as Topic ; Humans ; Immunotherapy ; Skin Neoplasms/immunology ; Skin Neoplasms/pathology ; Skin Neoplasms/therapy ; Treatment Outcome
    Chemical Substances Antineoplastic Agents, Immunological
    Language English
    Publishing date 2020-03-24
    Publishing country England
    Document type Congress
    ISSN 1750-7448
    ISSN (online) 1750-7448
    DOI 10.2217/imt-2020-0042
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma.

    Palmieri, Giuseppe / Puzanov, Igor / Massi, Daniela / Ascierto, Paolo Antonio

    Frontiers in oncology

    2021  Volume 11, Page(s) 728113

    Language English
    Publishing date 2021-07-09
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2021.728113
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Methylation‑sensitive restriction enzyme‑droplet digital PCR assay for the one‑step highly sensitive analysis of DNA methylation hotspots.

    Gattuso, Giuseppe / Lavoro, Alessandro / Caltabiano, Rosario / Madonna, Gabriele / Capone, Mariaelena / Ascierto, Paolo Antonio / Falzone, Luca / Libra, Massimo / Candido, Saverio

    International journal of molecular medicine

    2024  Volume 53, Issue 5

    Abstract: DNA methylation is an epigenetic modification that plays a key role in several cellular processes mediating the fine regulation of gene expression. Aberrant DNA methylation is observed in a wide range of pathologies, including cancer. Since these DNA ... ...

    Abstract DNA methylation is an epigenetic modification that plays a key role in several cellular processes mediating the fine regulation of gene expression. Aberrant DNA methylation is observed in a wide range of pathologies, including cancer. Since these DNA modifications are transferred to the cell progenies and are stable over the time, the analysis of DNA methylation status has been proposed for diagnostic and prognostic purposes in cancer. Currently, DNA bisulfite conversion is the gold standard method for the high‑throughput analysis of DNA methylation alterations. However, bisulfite treatment induces DNA fragmentation affecting its quality for the downstream analyses. In this field, it is mandatory to identify novel methods to overcome the limits of conventional approaches. In the present study, the Methylation‑Sensitive Restriction Enzyme‑droplet digital PCR (MSRE‑ddPCR) assay was developed as a novel sensitive method for the analysis of DNA methylation of short genomic regions, combining the MSRE assay with the high‑sensitivity ddPCR and using an exogenous methylation sequence as control. Setup and validation experiments were performed analyzing a methylation hotspot of the
    MeSH term(s) Humans ; DNA Methylation/genetics ; Melanoma/diagnosis ; Melanoma/genetics ; Polymerase Chain Reaction/methods ; DNA/genetics ; Sulfites
    Chemical Substances hydrogen sulfite (OJ9787WBLU) ; DNA (9007-49-2) ; Sulfites
    Language English
    Publishing date 2024-03-15
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 1444428-8
    ISSN 1791-244X ; 1107-3756
    ISSN (online) 1791-244X
    ISSN 1107-3756
    DOI 10.3892/ijmm.2024.5366
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4942: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Sonic hedgehog pathway for the treatment of inflammatory diseases: implications and opportunities for future research.

    Palla, Marco / Scarpato, Luigi / Di Trolio, Rossella / Ascierto, Paolo Antonio

    Journal for immunotherapy of cancer

    2022  Volume 10, Issue 6

    Abstract: The Sonic hedgehog (Shh) signaling pathway is an essential pathway in the human body that plays an important role in embryogenesis and tissue homeostasis. Aberrant activation of this pathway has been linked to the development of different diseases, ... ...

    Abstract The Sonic hedgehog (Shh) signaling pathway is an essential pathway in the human body that plays an important role in embryogenesis and tissue homeostasis. Aberrant activation of this pathway has been linked to the development of different diseases, ranging from cancer to immune dysregulation and infections.Uncontrolled activation of the pathway through sporadic mutations or other mechanisms is associated with cancer development and progression in various malignancies, such as basal cell carcinoma, medulloblastoma, pancreatic cancer, breast cancer and small-cell lung carcinoma. Targeted inhibition of the pathway components has therefore emerged as an attractive and validated therapeutic strategy for the treatment of a wide range of cancers. Currently, two main components of the pathway, the smoothened receptor and the glioma-associated oncogene homolog transcriptional factors, have been investigated for the development of targeted drugs, leading to the marketing authorization of three smoothened receptor inhibitors for the treatment of basal cell carcinoma and acute myeloid leukemia.The Shh pathway also seems to be involved in regulating the immune response, possibly playing a role in immune system evasions by tumors, development of autoimmune diseases, such as rheumatoid arthritis and Crohn's disease, airway inflammation, and diseases related to aberrant activation of T-helper 2 cellular response, such as allergy, atopic dermatitis, and asthma.Finally, the Shh pathway is involved in pathogen-mediated infection, including influenza-A and, more recently, SARS-CoV-2 viruses. Therefore, agents that inhibit the Shh signaling pathway might be used to treat pathogenic infections, shifting the therapeutic approach from strain-specific treatments to host-based strategies that target highly conserved host targets.
    MeSH term(s) COVID-19 ; Carcinoma, Basal Cell ; Cerebellar Neoplasms ; Hedgehog Proteins ; Humans ; Lung Neoplasms ; Medulloblastoma ; SARS-CoV-2 ; Signal Transduction/genetics ; Smoothened Receptor/metabolism ; Smoothened Receptor/therapeutic use
    Chemical Substances Hedgehog Proteins ; Smoothened Receptor
    Language English
    Publishing date 2022-03-28
    Publishing country England
    Document type Editorial
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2021-004397
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: IL-6 modulation for COVID-19: the right patients at the right time?

    Ascierto, Paolo Antonio / Fu, Binqing / Wei, Haiming

    Journal for immunotherapy of cancer

    2021  Volume 9, Issue 4

    Abstract: The ongoing pandemic caused by the novel coronavirus SARS-CoV-2 has disrupted the global economy and strained healthcare systems to their limits. After the virus first emerged in late 2019, the first intervention that demonstrated significant reductions ... ...

    Abstract The ongoing pandemic caused by the novel coronavirus SARS-CoV-2 has disrupted the global economy and strained healthcare systems to their limits. After the virus first emerged in late 2019, the first intervention that demonstrated significant reductions in mortality for severe COVID-19 in large-scale trials was corticosteroids. Additional options that may reduce the burden on the healthcare system by reducing the number of patients requiring intensive care unit support are desperately needed, yet no therapy has conclusively established benefit in randomized studies for the management of moderate or mild cases of disease. Severe COVID-19 disease is characterized by a respiratory distress syndrome accompanied by elevated levels of several systemic cytokines, in a profile that shares several features with known inflammatory pathologies such as hemophagocytic lymphohistiocytosis and cytokine release syndrome secondary to chimeric antigen receptor (CAR) T cell therapy. Based on these observations, modulation of inflammatory cytokines, particularly interleukin (IL)-6, was proposed as a strategy to mitigate severe disease. Despite encouraging recoveries with anti-IL-6 agents, especially tocilizumab from single-arm studies, early randomized trials returned mixed results in terms of clinical benefit with these interventions. Later, larger trials such as RECOVERY and REMAP-CAP, however, are establishing anti-IL-6 in combination with steroids as a potential option for hypoxic patients with evidence of hyperinflammation. We propose that a positive feedback loop primarily mediated by macrophages and monocytes initiates the inflammatory cascade in severe COVID-19, and thus optimal benefit with anti-IL-6 therapies may require intervention during a finite window of opportunity at the outset of hyperinflammation but before fulminant disease causes irreversible tissue damage-as defined clinically by C reactive protein levels higher than 75 mg/L.
    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19/virology ; Cytokines/immunology ; Cytokines/metabolism ; Humans ; Inflammation/immunology ; Inflammation/metabolism ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/immunology ; Interleukin-6/metabolism ; Macrophages/drug effects ; Macrophages/immunology ; Macrophages/metabolism ; Monocytes/drug effects ; Monocytes/immunology ; Monocytes/metabolism ; Pandemics ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/physiology
    Chemical Substances Antibodies, Monoclonal, Humanized ; Cytokines ; Interleukin-6 ; tocilizumab (I031V2H011)
    Language English
    Publishing date 2021-04-23
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2020-002285
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top